Ziprasidone

Limits on what this shows

• Null/negative findings: No study reported mitochondrial function data at standard oral therapeutic ziprasidone exposure in vivo in either species.
• At-risk subgroups: Not established; theoretical and tissue-dependent only.

Regulatory status

Not addressed in the FDA label.

Population evidence

Molecules 2020 (PMID 32937854), PC12 cells: ziprasidone alone promoted nuclear translocation of Nrf2 and activation of its antioxidant target genes, and prevented rotenone-induced cell death and intracellular ROS production; the protective effect was completely blocked by a serotonin 5-HT1A receptor antagonist, implicating 5-HT1A-receptor-dependent signaling as the mechanism. Biomedicines 2022;10(5):976 (PMID 35625713), rabbit isolated atrial tissue and myocytes: acute ziprasidone (100 microgram/mL) increased mitochondrial ROS by 87 percent (80±6 to 150±6 delta F/F0, p<0.05); this entry shares its source with Oxidative stress above and ATP production below, see Overlap map.

Mechanism

In the neuronal model, ziprasidone activates a 5-HT1A-receptor-dependent Nrf2 antioxidant response that protects mitochondria from an external toxin (rotenone). In the cardiac model, ziprasidone alone, with no added toxin, directly increased mitochondrial ROS production, proposed to activate CaMKII-dependent arrhythmogenic signaling. No human mitochondrial-marker study in ziprasidone-treated patients was located.

Counter-evidence held on record

The two available drug-specific studies used different tissues (neuronal cell line versus isolated cardiac tissue), different exposure paradigms (chronic co-treatment with an external toxin versus acute exposure alone), and reached opposite conclusions. Neither is a human clinical mitochondrial-function study. Do not interpret either finding as support for mitochondrial-support supplementation (for example coenzyme Q10, alpha-lipoic acid) in patients on ziprasidone; no clinical trial evidence supports this.

Limits on what this shows

• Null/negative findings: The one human in vivo cohort (PMID 33628026) found no significant pre/post change in five oxidative stress biomarkers for ziprasidone specifically, in contrast to clozapine, olanzapine, and quetiapine. This is the single most important counter-evidence in this entry and is why the grade is not higher.
• At-risk subgroups: Not established in humans; the animal and in vitro pro-oxidant signal is concentration- and tissue-dependent (plasma spike and isolated cardiac tissue, not oral therapeutic dosing in an intact organism).

Regulatory status

Not addressed in the FDA label as a redox or nutrient finding. The label separately documents that about two-thirds of ziprasidone's own metabolism proceeds via glutathione conjugation plus aldehyde oxidase reduction (see PK basis), a cofactor-consuming pathway plausibly relevant to this category, though not itself tested as a redox-status marker.

Population evidence

Dietrich-Muszalska A, Kolodziejczyk-Czepas J, Nowak P., Neuropsychiatr Dis Treat 2021 (PMID 33628026): 60 schizophrenia patients across six atypical antipsychotics including ziprasidone, baseline versus 4-week endpoint, five oxidative stress biomarkers (FRAP, TBARS, 4-HNE, 3-NT, urinary F2-isoprostanes). Clozapine, olanzapine, and quetiapine showed significant antioxidant benefit (F2-isoprostane reductions of about 42 to 82 percent, FRAP increases of about 65 to 81 percent); risperidone, aripiprazole, and ziprasidone showed differences between baseline and endpoint that "were not significant," a null, in vivo, drug-specific, Tier A finding for ziprasidone. Three independent in vitro human-plasma studies, all Tier B, from the same laboratory: Dietrich-Muszalska A et al., Neurochem Res 2013 (PMID 23619559), comparing ziprasidone, clozapine, and haloperidol on lipid peroxidation in human plasma (full text access blocked this session; title and cohort confirmed via listing page); Dietrich-Muszalska A et al., Schizophr Res Treatment 2014 (PMID 25061527), Aronia melanocarpa polyphenols reduced ziprasidone-induced plasma lipid peroxidation; Dietrich-Muszalska A et al., Int J Mol Sci 2025;26(21):10430 (PMID 41226471), all three tested ziprasidone concentrations (40, 139, 250 ng/mL) significantly elevated TBARS versus control (p<0.05) in human plasma (n=3 donors per condition), partly reversed by curcumin. A rabbit isolated-atrium and myocyte study, Biomedicines 2022;10(5):976 (PMID 35625713), found acute ziprasidone (100 microgram/mL, 30-minute exposure) increased cytosolic ROS by 25 percent (108±8 to 135±6 delta F/F0, p<0.05) and mitochondrial ROS by 87 percent (80±6 to 150±6 delta F/F0, p<0.05), with downstream TNF-alpha and NLRP3 inflammasome upregulation. A rat cardiac study, Nikolić-Kokić A et al., J Toxicol Environ Health A 2018 (PMID 30036154), "Clozapine, ziprasidone, and sertindole-induced morphological changes in the rat heart and their relationship to antioxidant enzymes function," is drug-specific by title, but its numeric findings could not be retrieved during this review due to a tooling access limitation (see Sources access notes).

Mechanism

Proposed as direct pro-oxidant chemistry generating lipid peroxidation products in plasma and mitochondrial/cytosolic ROS in cardiac tissue. Ziprasidone's own metabolism consumes glutathione as a reducing cofactor (PK basis), a plausible but not directly tested contributor to reduced antioxidant reserve. The cardiac ROS findings are explicitly framed by their authors as feeding CaMKII-mediated arrhythmogenesis, part of the mechanism behind ziprasidone's own proarrhythmic, QT-prolonging pharmacology, not an independent nutrient-style finding; this entry records the redox marker itself (which the required category covers) while keeping that arrhythmia link separate from any nutrient-deficiency framing per Hard Rule 2.

Counter-evidence held on record

The in vitro plasma and isolated-tissue findings use spiked concentrations and acute ex vivo exposure, not oral therapeutic dosing in an intact organism; the one available in vivo human dataset found no significant change. Do not read the rabbit cardiac ROS finding as an independent oxidative-stress deficiency signal separate from ziprasidone's own arrhythmia mechanism; this entry shares its primary source with Mitochondrial burden and ATP production below, see Overlap map. Does not support antioxidant or glutathione-precursor supplementation (for example N-acetylcysteine, vitamin C, vitamin E) in patients on ziprasidone; no clinical trial evidence supports this, and the one human cohort found no measurable effect in either direction.

Limits on what this shows

• Null/negative findings: None ziprasidone-specific identified; this is an absence of any direct data, not a negative study.
• At-risk subgroups: Not established for ziprasidone. If the class mechanism applied at all, it would be expected to track the same long-term pediatric, treatment-weight-gain-associated pattern seen with risperidone, which ziprasidone's comparatively weight-neutral profile makes less likely.

Regulatory status

Not addressed in the FDA label; iron or ferritin status is not a labeled monitoring parameter.

Population evidence

No ziprasidone-specific human iron-status cohort was located despite searching PubMed directly with combined and individual iron, ferritin, hemoglobin, and anemia terms. Class extrapolation: Calarge CA et al., pediatric risperidone cohorts ( J Child Adolesc Psychopharmacol 2013, PMID 23480322; 2016, PMID 26894929; J Clin Psychiatry 2015, PMID 26301448), documented 45 percent iron depletion and 14 percent frank iron deficiency in long-term pediatric risperidone users, with low ferritin measured "despite appropriate dietary iron intake," pointing toward increased utilization or inflammation-driven sequestration rather than intake, plausibly linked to treatment-related weight gain; these cohorts studied risperidone, not ziprasidone. One ambiguous case report was located: Tabaac BJ, Tabaac V., Ther Adv Psychopharmacol 2015 (PMID 25653830), "Pica patient, status post gastric bypass, improves with change in medication regimen," describing a post-bariatric-surgery patient with pre-existing iron-deficiency anemia whose pica symptoms improved after a medication change; full text could not be retrieved during this review (see Sources access notes), and the direction of any ziprasidone-iron relationship in this report could not be confirmed, so it is not counted as either supporting or refuting evidence here.

Mechanism

The risperidone mechanism is itself only "plausibly linked" to weight gain and inflammation, not directly demonstrated even in that drug. Ziprasidone's comparatively weight-neutral profile (label: 10 percent versus 4 percent placebo crossed a 7 percent weight-gain threshold in schizophrenia trials, a modest difference) removes much of the plausibility for this specific pathway applying to ziprasidone with similar force.

Counter-evidence held on record

This is a pure class extrapolation (Hard Rule 6: the Calarge cohorts studied risperidone, not ziprasidone) resting on a mechanism that is only plausibly, not definitively, linked to weight gain even in risperidone. Ziprasidone's comparatively weight-neutral profile is itself evidence against this pathway applying with similar force, not for it. Do not supplement iron in a ziprasidone-treated patient without a lab-confirmed low ferritin or iron panel obtained for an independent clinical reason. This entry makes no standing dosing recommendation.

Limits on what this shows

• Why no grade: Both conditions for ungraded status are met: no Tier B or Tier C evidence supports even a yellow grade for ziprasidone specifically (the one identifiable class-level trace-element cohort explicitly excluded ziprasidone; see below), and no circulating claim was located naming ziprasidone and copper together for this review to rebut as white.

Channels tried

PubMed search-listing pages, multiple phrasings ("ziprasidone copper," "ziprasidone" AND "copper" as separate quoted terms, "ziprasidone AND (copper OR iron OR ferritin OR zinc)"); a general web search for "ziprasidone copper zinc trace elements schizophrenia," which returned only class-level schizophrenia trace-element literature, none isolating ziprasidone. NCBI E-utilities (esearch endpoint, connect_rejected by session proxy policy), Europe PMC REST API (HTTP 429 / proxy-rejected on repeated attempts across the session), Semantic Scholar Graph API (HTTP 429 on repeated attempts), Crossref API (HTTP 429 / proxy-rejected), and OpenAlex API (HTTP 429 on repeated attempts) were all attempted and blocked. DuckDuckGo and Bing search pages were blocked by robots.txt for this tool.

Outcome

Direct "ziprasidone copper" and "ziprasidone" AND "copper" PubMed queries returned zero genuine matches; the search engine fell back to unrelated trending or off-topic results in each case, confirmed by inspecting the returned titles. Chen J et al., Biol Trace Elem Res 2018 (PMID 28470477), 165 inpatients versus 614 controls, named only risperidone, clozapine, and aripiprazole among the studied antipsychotics; ziprasidone was confirmed absent from this cohort, so under the cohort test it provides no support, even at Tier C, for ziprasidone specifically. Saghazadeh A et al. 2020 (PMID 31800085, 39-study meta-analysis) and Herran A et al. 2000 (PMID 10788677, depot typical-neuroleptic cohort) are class-level copper-schizophrenia sources previously identified in this series; neither includes ziprasidone, and both describe an illness-associated, not drug-specific, copper signal (confounding by indication presumed under Hard Rule 6).

Genuine gap vs tooling limited

Assessed as substantially a genuine evidence gap for ziprasidone specifically, since the one class-level trace-element cohort that does exist explicitly excluded this drug. This is compounded by a real tooling limitation: Europe PMC, Semantic Scholar, Crossref, OpenAlex, and NCBI E-utilities were all rate-limited or policy-blocked for substantial portions of this specific review session, preventing a fully exhaustive multi-database search from being completed. A future revision should re-attempt the blocked channels before treating this gap as fully closed.

Limits on what this shows

• Null/negative findings: No study, ziprasidone-specific or otherwise, was located that tested for and found no microbiome effect for ziprasidone; this is an absence of any study, not a negative result.
• At-risk subgroups: If the class mechanism applied, it would be expected only in the minority of ziprasidone-treated patients who experience clinically meaningful weight gain, not the drug's typical weight-neutral course.

Regulatory status

Not addressed in the FDA label.

Population evidence

Direct PubMed searches ("ziprasidone AND microbiota," "ziprasidone AND microbiome") returned zero genuine results during this review. A dedicated narrative review, Int J Mol Sci 2026 (MDPI, "Antipsychotic-Induced Remodeling of the Gut Microbiota: Drug-Specific Patterns and Molecular Links to Metabolic Adverse Effects"), synthesizing 71 publications on olanzapine, risperidone, clozapine, quetiapine, aripiprazole, lurasidone, and amisulpride, did not include ziprasidone among the antipsychotics analyzed. Class extrapolation: Bahr SM et al. ( Transl Psychiatry 2015, PMID 26440540; EBioMedicine 2015, PMID 26870798) demonstrated in pediatric patients and mice that risperidone-associated weight gain is mechanistically mediated through gut microbiome shifts that suppress host energy expenditure, the strongest class-level precedent identified; these studies did not include ziprasidone.

Mechanism

The established mechanism in risperidone and olanzapine runs through treatment-associated weight gain altering the gut microbial community, which in turn affects host energy metabolism. Ziprasidone's comparatively weight-neutral clinical profile removes the proximate driver of this mechanism, so class-level plausibility for ziprasidone specifically is weak, though not entirely excluded, since a minority of ziprasidone-treated patients do gain weight.

Counter-evidence held on record

This is a pure class extrapolation; the drug most responsible for the class-level mechanism, olanzapine, per the review's own assessment of "strongest mechanistic evidence," is pharmacologically and metabolically the least similar to ziprasidone among the antipsychotics reviewed. No causal or even correlative ziprasidone-microbiome data exist to weigh against this absence; this entry shares its underlying weight-neutral-profile reasoning with Iron above, see Overlap map. No probiotic strain or dose has clinical trial support for any indication in ziprasidone-treated patients. Do not substitute probiotic supplementation for standard metabolic monitoring (weight, glucose, lipids) actually indicated for this drug.

Limits on what this shows

• Null/negative findings: No cohort study directly measuring hemoglobin or hematocrit change in ziprasidone-treated patients, beyond the premarketing pooled adverse-reaction rate, was located.
• At-risk subgroups: Not established beyond the general premarketing trial population.

Regulatory status

The FDA label lists anemia under infrequent (0.1 to 1.0 percent) adverse reactions in premarketing experience. It separately lists leukopenia/neutropenia (clinical trial and postmarketing reports) and agranulocytosis, including fatal cases, as reported hematologic adverse reactions without quantified incidence; these are white-cell, likely immune-mediated phenomena and are not counted toward this category.

Population evidence

FDA label (accessdata.fda.gov SPI): pooled premarketing trial adverse-reaction data, anemia infrequent (0.1-1.0%). Platanić Arizanović L et al., Int J Mol Sci 2023 (PMID 37240267), "Human Hemoglobin and Antipsychotics Clozapine, Ziprasidone and Sertindole": human erythrocytes tested for direct drug-hemoglobin interaction, drug-specific and Tier B; the full abstract text could not be retrieved during this review due to a tooling access limitation (see Sources access notes), so only the title, drug names, and model (human erythrocytes) are confirmed. Nair P, Lippmann S., Psychosomatics 2005 (PMID 15765830), "Blood dyscrasia with quetiapine and ziprasidone": case report, drug-specific by title; the specific type of cytopenia could not be confirmed from the retrieved listing entry.

Mechanism

Not established in the label or in the literature retrieved. The in vitro hemoglobin-interaction study (PMID 37240267) is the only mechanistic lead identified for this category, but its direction and magnitude could not be confirmed due to the access limitation noted above.

Counter-evidence held on record

The label's hematologic adverse-reaction list is dominated by white-cell effects (leukopenia, neutropenia, agranulocytosis including fatal cases), a separate, non-oxygen-delivery phenomenon not filed under this category. An infrequent (0.1-1.0%) premarketing rate cannot exclude confounding by the underlying psychiatric illness, concurrent medications, or chance; no study identified tested whether the signal is dose-related, reversible on discontinuation, or associated with any measurable iron, B12, or folate deficit. Do not attribute unexplained anemia in a ziprasidone-treated patient to the drug without first excluding standard causes, including iron, B12, and folate status directly. This entry does not support iron or vitamin supplementation; no dosing recommendation is made.

Limits on what this shows

• Null/negative findings: No study directly measures ATP production in ziprasidone-exposed tissue. PubMed was searched with combined and individual phrasings ("ziprasidone AND ATP," "ziprasidone AND bioenergetic," "ziprasidone AND mitochondrial") and returned no genuine drug-specific ATP-production matches (searches fell back to unrelated trending or off-topic results, confirmed by inspecting returned titles); Europe PMC, Semantic Scholar, Crossref, and OpenAlex were attempted but returned persistent rate-limiting throughout this review session (see Sources access notes). This is treated as a probable, though not fully confirmed, genuine gap for a direct ATP measurement, compounded by a real tooling limitation.
• At-risk subgroups: Not established.

Regulatory status

Not addressed in the FDA label.

Population evidence

No ziprasidone-specific ATP-production study was located. Class extrapolation: risperidone, Toxicol In Vitro 2024 (PMID 39237056), human peripheral blood monocytes in vitro, decreased ATP production in isolated mitochondria at about 70 micromolar, a supratherapeutic concentration. Adjacent, ziprasidone-specific evidence: the rabbit atrial mitochondrial ROS increase (PMID 35625713, cited under Mitochondrial burden and Oxidative stress above) is mechanistically related to oxidative-phosphorylation efficiency but does not itself measure ATP; see Overlap map.

Mechanism

Plausible via the same receptor and membrane pharmacology implicated in ziprasidone's own cardiac oxidative-stress finding, and via general class-level precedent for antipsychotic mitochondrial bioenergetic effects at supratherapeutic concentrations; not directly demonstrated for ziprasidone at any concentration or in any tissue.

Counter-evidence held on record

This entry rests on class extrapolation (Hard Rule 6 applies: the risperidone finding does not establish a ziprasidone effect) plus indirect, non-ATP, within-drug mitochondrial ROS evidence; it is not itself an ATP measurement. See Overlap map for its shared basis with Mitochondrial burden and Oxidative stress. Does not support ATP-support supplementation (for example coenzyme Q10, creatine, ribose) in patients on standard therapeutic ziprasidone dosing.